2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH SILKE GILLESSEN
Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC)

VIEW ALL ADV PROSTATE VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH JONATHAN ROSENBERG
Results from CALGB 90601 in Metastatic Urothelial Carcinoma

VIEW ALL ADV BLADDER VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH CORA STERNBERG
SAUL Trial Data: Real World Experience of Atezolizumab in Carcinomas of the Urinary Tract

VIEW ALL UTUC VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH TANYA DORFF
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

VIEW ALL mHSPC VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

GU Cancers Symposium 2014 - Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study - Session Highlights

SAN FRANCISCO, CA USA (UroToday.com) - Dr. Christos Mikropoulos reported on results from the initial screening round of the IMPACT study. IMPACT is an international consortium of 62 centers in 20 countries evaluating the use of targeted prostate cancer screening in men with BRCA1/2 mutations.

gucancerssympalt thumbIt is known that men with germline BRCA1/2 mutations have a higher risk of developing prostate cancer than non-carriers. 2 481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls) of whom 199 (8%) presented with a PSA greater than 3ng/ml were enrolled into this study. One-hundred sixty-two prostate biopsies were performed and diagnosed 59 prostate cancers (18 BRCA1 carriers, ten BRCA1 controls; 24 BRCA2 carriers, seven BRCA2 controls). A significant difference in detecting intermediate- or high-risk disease was observed inBRCA2 carriers using a PSA threshold of 3.0 ng/ml, positive predictive value (PPV) of 48%, which is almost double that reported in population screening studies.

This early data support the use of targeted PSA screening, based on BRCA genotype (majority of BRCA1/2 mutation carriers), as these men are at higher risk of prostate cancer detection at the time of biopsy.

Highlights of a presentation by Christos Mikropoulos, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

The Institute of Cancer Research, London, England 

Written by Reza Mehrazin, MD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe